The FDA this week approved Sanofi's Sarclisa for the treatment of...

...relapsed refractory multiple myeloma in patients who have already tried at least two other therapies. This marks Sanofi's first approval for a wholly owned oncology drug since 2010. Among the most advantaged therapies in the multiple myeloma class are Celgene's Revlimid, which holds preferred status for 11% of covered lives (growing to 56% with prior authorization and/or step therapy), and Thalomid, another Celgene drug, which holds preferred status for 14% of covered lives (growing to 47% with PA/ST).

SOURCE: MMIT Analytics, as of 3/4/20